Retinal glial activation in diabetic retinopathy: therapeuticimpact of multikinase inhibition with sorafenib
Conclusions: Sorafenib attenuates retinal glial activation and neuroinflammatory changes in experimental diabetic retinopathy, suggesting its potential as a neuroprotective and antifibrotic agent. Targeted kinase inhibition may represent a promising adjunct strategy in early-stage disease management.
Authors
- K.O. Usenko (ORCID: https://orcid.org/0000-0001-9907-6109)
- С. В. Зябліцев (ORCID: https://orcid.org/0000-0002-5309-3728)
- Olena O. Dyadyk
- Danylo I Yevstifeiev (ORCID: https://orcid.org/0009-0002-4166-6397)
- Kateryna I. Popova
Institutions
- Shupyk National Healthcare University of Ukraine (UA)
- Bogomolets National Medical University (UA)
Publication Details
- Journal
- Wiadomości Lekarskie
- Published
- 2025-07-30
- DOI
- https://doi.org/10.36740/wlek/208991
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00